The Avacta share price is soaring. Should I buy?

The Avacta share price jumped yesterday by almost 5%. But have I missed my opportunity? Here’s my take on the biotech firm.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

The Avacta (LSE: AVCT) share price soared yesterday by almost 5%. Since the beginning of the year, the shares have rallied by nearly 50% and by over 65% in the past 12 months. Most of the gain has come this year, but during the last month, the Avacta share price tumbled by over 20%. For now, I’ve placed the stock on my watch list, but I think the biotech firm has lots of potential.

The test

The AIM-listed firm develops diagnostics and cancer therapies. The current CEO, Alastair Smith is the founder of the company. He has been responsible for the the management, strategic development and fundraising since Avacta listed on the junior market in 2006.

Inflation Is Coming

Inflation is out of control, and people are running scared. But right now there’s one thing we believe Investors should avoid doing at all costs… and that’s doing nothing. That’s why we’ve put together a special report that uncovers 3 of our top UK and US share ideas to try and best hedge against inflation… and better still, we’re giving it away completely FREE today!

Click here to claim your copy now!

But what has caught the attention of most investors is its rapid coronavirus test. These type of tests are intended to provide a cost effective and fast way of detecting individuals who have Covid-19. And Avacta has developed one that has so far yielded good results.

Recent news

Just yesterday, the firm announced that its test can detect the Delta variant, the strain which was first identified in India. Of course, the market reacted positively to this news and the shares jumped by almost 5%.

The Delta variant is spreading very quickly across the globe. And it may rapidly become the dominant strain worldwide. But there have been some concerns that Avacta may be late to the market with its Covid-19 test.

I personally think the rapid test remains important, especially now that it can detect this variant. It should also help the world get back to some kind of normality. It could mean that workers can go back to offices and large events can take place.

Bright side

As I mentioned, over the past month, the Avacta share price has fallen. But I think the sell-off is an overreaction. After all, this month the company has made a series of positive announcements.

On 7 June, Avacta confirmed that it had received UK approval for its rapid test. This was followed by the sign-off from the European regulator allowing the company to place its product on the market in 27 countries of the European Union.

Avacta also struck a deal with Calibre Scientific to distribute its tests in the UK and Europe. While Calibre’s headquarters is in Los Angeles, California, it has a global reach extending to over 100 countries. To me, this means that Avacta has the potential to distribute its rapid coronavirus test outside the UK and Europe.

But despite this good news, I think investors are disappointed that this hasn’t resulted in any sales yet. While Avacta is generating some revenue, it’s loss-making. It’s also worth noting here that the biotech firm now has the distribution infrastructure in place. But it has yet to sell its tests. And there’s no guarantee that major companies and other large-scale end users will buy the product.

My view

I reckon there could be a lot of upside with the Avacta share price. But I’d like to see some evidence that it’s selling its rapid coronavirus tests before I dip my toe in. Hence I’ll only be monitoring the stock for now.

Is this little-known company the next ‘Monster’ IPO?

Right now, this ‘screaming BUY’ stock is trading at a steep discount from its IPO price, but it looks like the sky is the limit in the years ahead.

Because this North American company is the clear leader in its field which is estimated to be worth US$261 BILLION by 2025.

The Motley Fool UK analyst team has just published a comprehensive report that shows you exactly why we believe it has so much upside potential.

But I warn you, you’ll need to act quickly, given how fast this ‘Monster IPO’ is already moving.

Click here to see how you can get a copy of this report for yourself today

Nadia Yaqub has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Should you invest the value of your investment may rise or fall and your Capital is at Risk. Before investing your individual circumstances should be considered, so you should consider taking independent financial advice.

More on Investing Articles

Female florist with Down's syndrome working in small business
Investing Articles

2 promising penny stocks to buy on the dip

As stock markets continue to correct, I am hunting for oversold penny stocks that I think could help turbocharge my…

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

I wouldn’t buy Bitcoin today. FTSE value stocks look much better value to me

Now looks like a promising time to buy UK value stocks, while Bitcoin still looks far too risky for me.

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

The Rolls-Royce share price is below 85p. Here’s what I’m doing!

The Rolls-Royce share price has suffered this year. Trading for below 85p, this Fool decides whether this is an opportunity…

Read more »

A young woman sitting on a couch looking at a book in a quiet library space.
Investing Articles

4 dividend stocks to buy as inflation soars!

I'm hunting for the best dividend stock to invest in as global inflation soars. Here are several high-dividend-yield shares that…

Read more »

Happy young female stock-picker in a cafe
Investing Articles

UK shares to buy now: 3 big fallers I’d snap up

Our writer thinks this trio of strong business performers could be attractive UK shares to buy now for his portfolio.

Read more »

Lady researching stocks
Investing Articles

Could a falling stock market help me get rich?

When the stock market falls, what does it mean for our writer's portfolio? Here's why it could be an opportunity.

Read more »

Hand holding pound notes
Investing Articles

Should I buy these two 12%-yielding dividend shares for my Stocks and Shares ISA?

Do these double-digit dividend yielders offer our author the right balance of risk and reward for his Stocks and Shares…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 reasons to buy Lloyds shares at 43p

Our writer outlines three factors that make him bullish on Lloyds shares, as well as one noteworthy risk facing the…

Read more »